Sandoz Inc. received FDA approval to market the generic version of tafluprost (ANDA 209040) on Jan. 28, 2022, introducing a new low-cost option to the ocular hypertension and open-angle glaucoma market. This approvals marks a direct therapeutic alternative to the originator drug and signals Sandoz’s strategy to capitalize on generic demand within the eye-care segment.